Medical Oxygen Manufacturing Plant Project Report (DPR) 2026

What is medical oxygen?

Medical oxygen is oxygen made, tested, labeled and distributed as a drug for treating patients. Hospitals use it for pneumonia, surgery and anesthesia, intensive care, newborn care and long-term therapy for chronic lung disease. Chemically it is the same molecule that steel mills buy, so the difference lies in documented quality and traceability rather than in the separation equipment.

Grades are set by pharmacopoeias. Oxygen USP calls for at least 99.0% and the European Pharmacopoeia monograph for at least 99.5%. One Indian hospital tender asks for at least 99.6% under the Indian Pharmacopoeia, with limits on carbon monoxide and carbon dioxide. A separate 93% grade, made by pressure swing adsorption, serves on-site hospital systems.

The product falls under Harmonized System subheading 2804.40, oxygen, which does not separate medical from industrial material. Forms of sale include bulk cryogenic liquid delivered to hospital tanks, high-pressure cylinders and small home-care containers. For transport, compressed oxygen is UN1072 and refrigerated liquid oxygen is UN1073.

Medical oxygen market overview and global demand

The global market is worth about USD 11.6 billion in 2025, based on Credence Research's global medical oxygen study of USD 10.79 billion for 2024 and a 7.67% CAGR, which points to USD 19.33 billion by 2032. It forms part of the broader medical gases category, which also covers nitrous oxide and medical air.

Clinical need is far larger than current supply in poorer countries. The Lancet Global Health Commission reported in 2025 that about 374 million people need medical oxygen each year, and 82% of them live in low- and middle-income countries. Acute medical and surgical care alone needs at least 1.2 billion normal cubic meters a year, or roughly 1.7 million metric tons. Only about 30% of people needing acute oxygen in those countries receive adequate therapy, and closing that gap would cost an estimated USD 6.8 billion a year.

Demand can also spike. COVID-19 added about 1.9 billion cubic meters in 2021, and India's government reported liquid medical oxygen output rising from about 5,700 metric tons a day in August 2020 to 9,690 tons by May 2021, partly by diverting industrial capacity.

Trade is thin because oxygen is costly to move. World exports under HS 2804.40 were about USD 215 million in 2023, led by France, Belgium, the Czech Republic, Germany and the Netherlands, a pattern consistent with short cross-border hauls. Germany and the Netherlands also rank among the leading importers. Supply is therefore regional, and a plant competes within a delivery radius rather than against world prices.

Buyers are hospitals and hospital groups, public health systems, home-care providers, cylinder distributors and, for the rest of the output, industrial users.

Medical oxygen manufacturing process

Two routes exist. Pressure swing adsorption passes air over zeolite to give about 93% oxygen, and it suits a hospital's own small unit. A commercial producer selling pharmacopoeial liquid and cylinder oxygen uses cryogenic air separation, which is the route assumed here. It also yields nitrogen and argon, which matter because a plant cannot sell medical oxygen alone at full load.

• Air compression and precooling. Filtered ambient air is compressed in stages and chilled to about 5–12 degrees Celsius. Site air quality checks matter because air is the starting material.
• Purification. Molecular sieve adsorbers strip out moisture, carbon dioxide and hydrocarbons, which would otherwise freeze in the cold box or concentrate dangerously in liquid oxygen.
• Cooling and liquefaction. A main heat exchanger and turbo-expander bring the air close to its liquefaction point. A nitrogen liquefier adds the refrigeration needed to draw product as liquid rather than gas, and that step drives the power bill.
• Distillation. Columns in the cold box separate components by boiling point. Oxygen collects as liquid, nitrogen goes overhead and a side column recovers argon.
• Testing and release. Bulk tanks dedicated to medical quality are sampled for assay and impurities such as carbon monoxide and carbon dioxide. Continuous analyzers feed trend records that regulators expect to see.
• Filling and distribution. Liquid goes by cryogenic tanker to hospital tanks. For cylinders, a pump and vaporizer feed a filling manifold, where each returned cylinder is inspected, evacuated or purged, filled, leak-tested, sealed and labeled by batch.

Cylinder handling causes more regulatory attention than distillation does. Returned containers can bring in contamination, and mix-ups between gases have caused patient harm, so rules focus on dedicated connections, residual pressure checks and batch records. Much of the medical compliance cost therefore sits at the filling station.

Medical oxygen plant setup cost

The reference plant produces 100 metric tons of liquid gases a day, split about 75 tons oxygen, 22 tons nitrogen and 3 tons argon, close to the mix at disclosed plants. It adds a filling station for about 800–1,000 cylinders a day. Total CapEx is estimated at USD 25–55 million, covering land, the separation unit, storage, filling, a tanker and cylinder pool, utilities, preoperative costs and working capital.

Three disclosed projects anchor the range. Air Liquide's plant at Kosi, India, cost about USD 42 million, converted from rupees at an assumed rate, for more than 365 tons a day. INOX Air Products announced about USD 274 million, also converted at an assumed rate, for eight units totaling more than 1,500 tons a day in 2021, or about USD 34 million each. Air Liquide's Sydney expansion was reported at USD 32.3 million for a unit processing 15,000 normal cubic meters of air an hour, roughly this plant's scale by estimate.

Scaled by the six-tenths rule, with assumed escalation, the Indian projects give about USD 21–30 million for the separation unit. The Sydney figure, with an assumed 1.1x greenfield factor, gives about USD 36 million. An assumed 15–20% for filling and fleets leads to USD 25–35 million in Asia. A high-cost site is USD 40–55 million, with the top end reflecting an assumed larger fleet and site premium.

For the land row, the plant needs about 40,000 square meters, an assumed figure well below the 18 acres in use at one U.S. project. At an assumed USD 15–60 per square meter, land costs USD 600,000 to USD 2.4 million, or about 4% of mid-range CapEx. U.S. and EU sites can exceed that range.

The separation unit dominates the investment. Operating cost then depends on the power contract and on how far the product travels.

The full report can be customized to any country or region.